Shubber Z, Mills EJ, Nachega JB, Vreeman R, Freitas M, Bock P, et al. Patient-reported barriers to adherence to antiretroviral therapy: a systematic review and meta-analysis. PLoS Med. 2016;13(11):e1002183. https://doi.org/10.1371/journal.pmed.1002183.

Article  PubMed  PubMed Central  Google Scholar 

Centers for Disease Control and Prevention: Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas, 2019. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (2021). Accessed February 10, 2023.

Centers for Disease Control and Prevention. Ending the HIV Epidemic in the U.S. (EHE). https://www.cdc.gov/endhiv/treat.html. Accessed 10 Feb 2023.

ViiV Healthcare: Cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension (Cabenuva) [package insert]. U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212888s005s006lbl.pdf Accessed April 13, 2023.

Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C. Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet. 2021;60(7):835–53. https://doi.org/10.1007/s40262-021-01005-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliveira M, Ibanescu RI, Anstett K, Mésplède T, Routy JP, Robbins MA, et al. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. Retrovirology. 2018;15(1):56. https://doi.org/10.1186/s12977-018-0440-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Azijn H, Tirry I, Vingerhoets J, de Béthune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718–27. https://doi.org/10.1128/aac.00986-09.

Article  CAS  PubMed  Google Scholar 

•• Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124–35. https://doi.org/10.1056/NEJMoa1909512. This study showed that long-acting cabotegravir plus rilpivirine is non-inferior to oral dolutegravir-abacavir-lamivudine for the maintenance of viral suppression after oral induction.

Article  CAS  PubMed  Google Scholar 

Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8(4):e185–e96. https://doi.org/10.1016/s2352-3018(20)30340-4.

Article  CAS  PubMed  Google Scholar 

•• Swindells S, Andrade-Villanueva J-F, Richmond GJ, Rizzardini G, Baumgarten A, Masiá M, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. New England Journal of Medicine. 2020;382(12):1112–23. https://doi.org/10.1056/NEJMoa1904398. This study showed that long-acting cabotegravir plus rilpivirine is non-inferior to standard oral therapy for the maintenance of viral suppression.

Article  CAS  PubMed  Google Scholar 

Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al. Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022;36(2):185–94. https://doi.org/10.1097/qad.0000000000003025.

Article  CAS  PubMed  Google Scholar 

•• Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994–2005. https://doi.org/10.1016/s0140-6736(20)32666-0. This study showed that long-acting cabotegravir plus rilpivirine dosed every 8 weeks is non-inferior to dosing every 4 weeks for the maintenance of viral suppression.

Article  CAS  PubMed  Google Scholar 

Overton ET, Richmond G, Rizzardini G, Thalme A, Girard PM, Wong A, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis. 2023; https://doi.org/10.1093/cid/ciad020.

•• Ramgopal M, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, et al. SOLAR 12-month results: randomized switch trial of cabotegravir+rilpivirine vs oral bictegravir/emtricitabine/tenofovir alafenamide [CROI Abstract 191]. In: Abstracts From CROI 2023 Conference on Retroviruses and Opportunistic Infections. CROI 2023 Abstract eBook; 2023. p. 483. This study showed that long-acting cabotegravir plus rilpivirine dosed every 8 weeks is non-inferior to oral bictegravir-emtricitabine-tenofovir alafenamide for the maintenance of viral suppression.

Google Scholar 

United States Food and Drug Administration: FDA approves cabenuva and vocabria for the treatment of HIV-1 infection. https://www.fda.gov/drugs/human-immunodeficiency-virus-hiv/fda-approves-cabenuva-and-vocabria-treatment-hiv-1-infection (2021). Accessed February 16, 2023.

Johnson & Johnson: U.S. FDA approves CABENUVA (rilpivirine and cabotegravir) for use every two months, expanding the label of the first and only long-acting HIV treatment. https://www.jnj.com/u-s-fda-approves-cabenuva-rilpivirine-and-cabotegravir-for-use-every-two-months-expanding-the-label-of-the-first-and-only-long-acting-hiv-treatment (2022). Accessed February 16, 2023.

Viiv Healthcare: ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for virologically suppressed adolescents living with HIV who are 12 years of age or older and weigh at least 35 kg. https://viivhealthcare.com/en-us/media-center/news/press-releases/2022/march/viiv-healthcare-announces-us-fda-approval-of-cabenuva/ (2022). Accessed April 13, 2023.

Flexner C, Thomas DL, Clayden P, Swindells S. What clinicians need to know about the development of long-acting formulations. Clin Infect Dis. 2022;75(Suppl 4):S487–s9. https://doi.org/10.1093/cid/ciac749.

Article  CAS  PubMed  Google Scholar 

Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57(1):106220. https://doi.org/10.1016/j.ijantimicag.2020.106220.

Article  CAS  PubMed  Google Scholar 

Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, et al. Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase 3 ATLAS and FLAIR trials. J Acquir Immune Defic Syndr. 2020;85(4):498–506. https://doi.org/10.1097/qai.0000000000002466.

Article  PubMed  PubMed Central  Google Scholar 

Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8(11):e679–e89. https://doi.org/10.1016/s2352-3018(21)00185-5.

Article  CAS  PubMed  Google Scholar 

• Cutrell AG, Schapiro JM, Perno CF, Kuritzkes DR, Quercia R, Patel P, et al. Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis. Aids. 2021;35(9):1333–42. https://doi.org/10.1097/qad.0000000000002883. This study examined risk factors associated with virologic failure among participants treated with long-acting cabotegravir-rilpivirine in phase 3 clinical trials.

Article  CAS  PubMed  Google Scholar 

•• Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (2023). Accessed April 6, 2023 2023. These guidelines provide detailed and up-to-date recommendations on the management of adults and adolescents with HIV.

Kenney S, Patel N, Hill L. Predictors of post switch viremia in patients on injectable cabotegravir/rilpivirine [CROI Abstract 516]. In: Abstracts From CROI 2023 Conference on Retroviruses and Opportunistic Infections. CROI 2023 Abstract eBook; 2023. p. 483.

Google Scholar 

Trezza C, Ford SL, Spreen W, Pan R, Piscitelli S. Formulation and pharmacology of long-acting cabotegravir. Curr Opin HIV AIDS. 2015;10(4):239–45. https://doi.org/10.1097/coh.0000000000000168.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brizzi M, Pérez SE, Michienzi SM, Badowski ME. Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment? Ther Adv Infect Dis. 2023;10:20499361221149773. https://doi.org/10.1177/20499361221149773.

Article  PubMed  PubMed Central  Google Scholar 

• de Los RP, Okoli C, Castellanos E, Allan B, Young B, Brough G, et al. Physical, emotional, and psychosocial challenges associated with daily dosing of HIV medications and their impact on indicators of quality of life: findings from the positive perspectives study. AIDS Behav. 2021;25(3):961–72. https://doi.org/10.1007/s10461-020-03055-1. This study examined challenges associated with daily oral antiretroviral therapy among people with HIV in 25 countries.

Article  Google Scholar 

Safreed-Harmon K, Anderson J, Azzopardi-Muscat N, Behrens GMN, d’Arminio Monforte A, Davidovich U, et al. Reorienting health systems to care for people with HIV beyond viral suppression. Lancet HIV. 2019;6(12):e869–e77. https://doi.org/10.1016/s2352-3018(19)30334-0.

Article  PubMed  Google Scholar 

Akinwunmi B, Buchenberger D, Scherzer J, Bode M, Rizzini P, Vecchio F, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries. Sex Transm Infect. 2021;97(8):566–73. https://doi.org/10.1136/sextrans-2020-054648.

Article  PubMed  Google Scholar 

Campbell CK, Dubé K, Sauceda JA, Ndukwe S, Saberi P. Antiretroviral therapy experience, satisfaction, and preferences among a diverse sample of young adults living with HIV. AIDS Care. 2022;34(9):1212–8. https://doi.org/10.1080/09540121.2021.2001783.

Article  PubMed  Google Scholar 

Dandachi D, Dang BN, Lucari B, Swindells S, Giordano TP. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care. 2021;33(6):801–9. https://doi.org/10.1080/09540121.2020.1764906.

Article  PubMed  Google Scholar 

Dubé K, Campbell DM, Perry KE, Kanazawa JT, Saberi P, Sauceda JA, et al. Reasons people living with HIV might prefer oral daily antiretroviral therapy, long-acting formulations, or future HIV remission options. AIDS Res Hum Retroviruses. 2020;36(12):1054–8. https://doi.org/10.1089/aid.2020.0107.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kerrigan D, Sanchez Karver T, Muraleetharan O, Savage V, Mbwambo J, Donastorg Y, et al. “A dream come true”: perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS One. 2020;15(6):e0234666. https://doi.org/10.1371/journal.pone.0234666.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Philbin MM, Parish CL, Kinnard EN, Reed SE, Kerrigan D, Alcaide ML, et al. Multisite study of women living with HIV’s perceived barriers to, and interest in, long-acting injectable antiretroviral therapy. J Acquir Immune Defic Syndr. 2020;84(3):263–70. https://doi.org/10.1097/qai.0000000000002337.

Article  PubMed  PubMed Central  Google Scholar 

Simoni JM, Beima-Sofie K, Mohamed ZH, Christodoulou J, Tapia K, Graham SM, et al. Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV. AIDS Patient Care STDS. 2019;33(3):104–11. https://doi.org/10.1089/apc.2018.0198.

Article  PubMed  PubMed Central  Google Scholar 

Simoni JM, Tapia K, Lee SJ, Graham SM, Beima-Sofie K, Mohamed ZH, et al. A conjoint analysis of the acceptability of targeted long-acting injectable antiretroviral therapy among persons living with HIV in the U.S. AIDS Behav. 2020;24(4):1226–36. https://doi.org/10.1007/s10461-019-02701-7.

Article  PubMed  PubMed Central